NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Oak Hill Bio

Oak Hill Bio

Private
AltrinchamHealthcare & Life Scienceshttps://oakhillbio.com/

Last Round

Series A

Jun 1, 2026

Total Funding Raised

$32.5M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Oak Hill Bio is a biotechnology company that acquires and develops deprioritized late-stage rare disease drugs.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

rare disease therapyorphan drugsdrug asset acquisitionclinical-stage biotechpharma spinoutAngelman syndromeantisense oligonucleotidelate-stage developmentASO therapyneurodevelopmental disordersvirtual biotechpharma licensingrare autoimmune diseasesprematurity complicationsrecombinant proteinsmall molecule therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Oak Hill Bio Comps

Public and private peers based on sector, stage, and business model.

Oak Hill Bio comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Oak Hill Bio Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AJun 1, 2026
SeedFeb 1, 2022
View all Funding Rounds

Key People

Founding team and executive leadership

Sharon Morriss

Chief Operating Officer

Executive Team

Oak Hill Bio Investors

Notable investors and investment history

Oak Hill Bio investors
InvestorRounds
Janus Henderson GroupSeries A
Balyasny Asset Management L.P.Series A
venBioSeries A
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 1, 2026

    $33M round led by Balyasny Asset Management, Janus Henderson, and venBio.

  • Apr 15, 2026

    Monthly visitors grew 161% MoM, reaching 2K.

View all signals

Oak Hill Bio Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Oak Hill Bio Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Oak Hill Bio's valuation, stock price, and market status.

Firmographic Details

HeadquartersAltrincham
Employee Range29
Year Founded2022
Last FundingJun 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.